This table provides information on the known or predicted interactions between lenacapavir (LEN), an HIV capsid inhibitor, and other drugs, including antiretroviral (ARV) drugs. (hiv.gov)
Due to the long half-life of the injectable formulation, this inhibitory effect may persist, and clinicians should continue to assess for drug interactions for up to 9 months after the last LEN injection. (hiv.gov)
The magnitude and significance of drug interactions are difficult to predict when several drugs with competing metabolic pathways are prescribed concomitantly. (hiv.gov)
People with HIV should be counseled about the importance of informing all their health care providers about their HIV regimen prior to starting any new concomitant medications (e.g., prescription, over the counter, and herbs or dietary supplements) to minimize the risk of drug-drug interactions. (hiv.gov)
Months after the1
May increase exposure and risk of adverse reactions to drugs primarily metabolized by CYP3A initiated within 9 months after the last subcutaneous dose of SUNLENCA. (nih.gov)
Issues1
Finally, we live in an age where the questions for analysis have broadened beyond the main issues confronting the U.S. Food and Drug Administration of 1954. (cdc.gov)
Increase1
LEN is a moderate cytochrome P450 (CYP) 3A4 inhibitor and may increase the concentration of drugs metabolized by CYP3A4. (hiv.gov)